Imexpharm Corporation · HOSE:IMP
Imexpharm — Q3 2026 Earnings Presentation
11 slides from Imexpharm's earnings presentation, October 2026
Slide 1: Investor Presentation Q3 and 9M2026
INVESTOR PRESENTATION IMEXPHARM CORPORATION Q3 and 9M2026 1
Slide 2: Strong ETC growth and a September rebound provide positive momentum heading into Q4
Strong ETC growth and a September rebound provide positive momentum heading into Q4 Net revenue 3Q September Net revenue VND 544 bn VND 198 bn ▼ 5% YoY ▼ 3% QoQ ETC ▲ 5% MoM ▲ 10% YoY EBITDA 3Q September EBITDA VND 127 bn VND 55 bn ▼ 3% YoY ▼ 10% QoQ ▲ 49% MoM PBT 3Q OTC September PBT VND 105 bn ▼ 6
Slide 3: Resilient profitability amid continued revenue challenges
Resilient profitability amid continued revenue challenges Year-end target completion Gross revenue ▼ 7% yoy 61% VND 1,961 billion 44,7% 41,5% 41,9% 41,0% Gross 39,5% 40,1% 39,6% profit margin Net revenue ▼ 8% yoy VND 1,652 billion 16,8% 16,7% 17,3% 14,3% 13,4% 15,0% Net 12,5% profit EBITDA ▬ 0% yoy
Slide 4: Sustainable profit growth driven by operational efficiency and cost optimization
Sustainable profit growth driven by operational efficiency and cost optimization VND bn 1.961 1.652 -309 685 -967 86 401 02 326 -362 Gross revenue Sales deduction Net revenue COGS Gross Profit SG&A expense Others PBT Int,Dep,Amor EBITDA YoY (7%) (3%) (8%) (11%) (4%) (8%) (1x%) 5% (7%) 0% 4
Slide 5: ETC recovery partially offset continued headwinds in the OTC channel
ETC recovery partially offset continued headwinds in the OTC channel Gross revenue contracted across both ETC and OTC OTC channel contracted 11% yoy, achieving 61% of year-end target 9M25 54% 43% 3% • 9M2026 revenue fell 11% YoY to VND 831 billion, 9M26 57% 41% 1% primarily driven by a 25% decline i
Slide 6: Costs remained well-controlled, reinforcing profitability despite top-line pressure
Costs remained well-controlled, reinforcing profitability despite top-line pressure COGS (VND bn) -11% • COGS decreased by 11% YoY, outpacing the decline in gross revenue, driven by the optimized management of product- based promotions. • IMP is proactively diversifying raw material sourcing to miti
Slide 7: EU-GMP facilities remain the key growth driver, contributing over 60% of revenue
EU-GMP facilities remain the key growth driver, contributing over 60% of revenue 11% 876 755 776 9M25 Revenue by Factory 715 39% IMP1 9M26 (VND Bn) 36% 9M26 IMP2 305 291 179 216 IMP3 IMP4 IMP1 IMP2 IMP3 IMP4 15% Production volume Factory • IMP3 Peni maintained 3% YoY growth in production volume Prod
Slide 8: Sustained strong position in Tier 2 tenders
Sustained strong position in Tier 2 tenders Market tender value IMP tender value (VND Tn) (VND Bn) 26,4 25,4 15.2% 15.2% %MS 23,7 20,5 0.9% 0.5% 1770,1 1.796,8 0.3% 0.5% 9M25 11,6 11,8 9M26 183,9 119,2 139,6 82,8 9M25 Tier 1 Tier 2 Tier 3-5 Tier 1 Tier 2 Tier 3-5 9M26 8
Slide 9: Expanding non-antibiotics to navigate headwinds; increasing MAs for global business
Expanding non-antibiotics to navigate headwinds; increasing MAs for global business 10.4% +10 +20 127 4.2% New SKUs New projects R&D pipeline 72% 29% 3.6% 3.0% 3.3% 2.1% 01 Lyophilized Powder for 0.9% 1.0% Injection granted MA in Singapore Antibiotics Cough medicine Digestive aid Analgesic and antip
Slide 10: 3Q2026 Market update
3Q2026 Market update Regulatory inspections and enforcement actions against pharmaceutical businesses have Increasingly stringent intensified, particularly in relation to taxation, prescription drugs, and pharmacy-only medicines. regulatory oversight and The Government is accelerating the finalizati
Slide 11: Thank You
Thank You For further discussion, please contact our IR team ir@imexpharm.com 11